Lookup NU author(s): Dr Andrew Gennery,
Dr Mary Slatter,
Professor Roderick Skinner
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2017 The American Society for Blood and Marrow Transplantation. Severe combined immunodeficiency (SCID) is effectively treated with hematopoietic cell transplantation (HCT), with overall survival approaching 90% in contemporary reports. However, survivors are at risk for developing late complications because of the variable durability of high-quality immune function, underlying genotype of SCID, comorbidities due to infections in the pretransplantation and post-transplantation periods, and use of conditioning before transplantation. An international group of transplantation experts was convened in 2016 to review the current knowledge of late effects seen in SCID patients after HCT and to develop recommendations for screening and monitoring for late effects. This report provides recommendations for screening and management of pediatric and adult SCID patients treated with HCT.
Author(s): Heimall J, Buckley RH, Puck J, Fleisher TA, Gennery AR, Haddad E, Neven B, Slatter M, Skinner R, Baker KS, Dietz AC, Duncan C, Griffith LM, Notarangelo L, Pulsipher MA, Cowan MJ
Publication type: Article
Publication status: Published
Journal: Biology of Blood and Marrow Transplantation
Print publication date: 01/08/2017
Online publication date: 04/05/2017
Acceptance date: 28/04/2017
ISSN (print): 1083-8791
ISSN (electronic): 1523-6536
Publisher: Elsevier Inc.
Altmetrics provided by Altmetric